FY2025 · ended Dec 31, 2025 · Revenue $30.91M, +209.1% YoY · Filed Mar 4, 2026
Verastem, Inc. (VSTM) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $30.9 million and a net loss of $209.5 million. As of Jun 30, 2026 it held $136.4 million in cash and investments and $2.6 million in total debt.
Revenue (TTM)
$87.53M
Net income (TTM)
$-202.70M
Operating cash flow (TTM)
$-162.19M
Free cash flow
$-104.80M
-95.2% vs prior year
EPS (TTM)
$-2.39
Dividend per share
None
Shares outstanding
87.84M
+70.6% vs prior year
Net cash
$133.74M
as of Jun 30, 2026
Operating margin
-182.6%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VSTM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- MA
- Headquarters
- Needham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1526119
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $30.9M | $10.0M | — | $2.6M | $2.1M |
| Operating income | -$170.1M | -$115.0M | -$92.1M | -$72.9M | -$61.4M |
| Net income | -$209.5M | -$130.6M | -$87.4M | -$73.8M | -$71.2M |
| Diluted EPS | -$3.02 | -$3.66 | -$3.96 | -$4.57 | -$4.90 |
| Operating cash flow | -$137.5M | -$104.8M | -$86.5M | -$63.7M | -$53.5M |
| Free cash flow | — | -$104.8M | — | — | -$53.7M |
| Total assets | $246.4M | $101.5M | $149.7M | $95.0M | $108.7M |
| Total liabilities | $189.2M | $130.4M | $71.2M | $47.7M | $21.1M |
| Stockholders' equity | $57.2M | -$28.9M | $57.4M | $47.4M | $87.6M |
| Cash and investments | $205.0M | $88.8M | $137.1M | $87.9M | $100.3M |
| Total debt | $535,000 | $42.3M | $41.6M | $26.0M | $2.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 14, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Results of operations, Officer or director change, Regulation FD disclosure, Other events
|
Oct 14, 2026 | Oct 12, 2026 |
| 8-K |
Current report
Material agreement, New debt, Regulation FD disclosure
|
Aug 7, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 23, 2026 | Jun 23, 2026 |
All 1000 Verastem, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.